导管内乳头状黏液性肿瘤手术中「观察等待」策略的风险
结果显示34.5%患者切除时已为浸润癌,过晚组并发症和死亡率最高,且24.9%过晚组有观察等待史,提示观察等待策略需谨慎。
要点
- 约三分之一IPMN患者切除时已进展为浸润癌。
- 过晚切除组并发症和死亡率显著高于过早和及时组。
- 有观察等待史的患者中24.9%最终切除时为浸润癌。
核心结论
- 在IPMN生物学和进展模式明确及指南建立前,观察等待策略应谨慎应用,尤其存在主胰管成分时。
- 三分之一的IPMN在切除时已达癌症阶段,但在专科转诊中心手术并发症和死亡率风险可控。
研究设计与样本
- 根据最终病理将切除时机分为过早组(腺瘤和低级别异型增生)、及时组(中级别异型增生和原位癌)和过晚组(浸润癌)。
主要发现
- 1439例中,过早组438例(30.4%),及时组504例(35.1%),过晚组497例(34.5%)。
- 影像学恶性标准检出率:过早组53/382(13.9%),及时组149/432(34.5%),过晚组341/385(88.6%)(P < .001)。
- 保留实质切除术式比例:过早组123/438(28.1%),及时组40/504(7.9%),过晚组5/497(1.0%)(P < .001)。
- 并发症发生率:过早组112/438(25.6%),及时组117/504(23.2%),过晚组158/497(31.8%)(P = .002)。
- 死亡率:过早组4例(0.9%),及时组4例(0.8%),过晚组13例(2.6%)(P = .03)。
临床怎么用
- 对IPMN患者选择观察等待时需评估恶性风险,尤其存在主胰管成分者应更积极考虑手术。
- 在专科中心,IPMN手术的并发症和死亡率在可接受范围内,支持适时手术干预。
局限性
- 单中心回顾性设计可能限制结果外推。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The natural history of intraductal papillary mucinous neoplasms (IPMNs) remains uncertain. The inconsistencies among published guidelines preclude accurate decision-making. The outcomes and potential risks of a conservative watch-and-wait approach vs a surgical approach must be compared. OBJECTIVE: To provide an overview of the surgical management of IPMNs, focusing on the time of resection. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted in a single referral center; all patients with pathologically proven IPMN who received a pancreatic resection at the institution between October 2001 and December 2019 were analyzed. Preoperatively obtained images and the medical history were scrutinized for signs of progression and/or malignant features. The timeliness of resection was stratified into too early (adenoma and low-grade dysplasia), timely (intermediate-grade dysplasia and in situ carcinoma), and too late (invasive cancer). The perioperative characteristics and outcomes were compared between these groups. EXPOSURES: Timeliness of resection according to the final pathological findings. MAIN OUTCOMES AND MEASURES: The risk of malignant transformation at the final pathology. RESULTS: Of 1439 patients, 438 (30.4%) were assigned to the too early group, 504 (35.1%) to the timely group, and 497 (34.5%) to the too late group. Radiological criteria for malignant conditions were detected in 53 of 382 patients (13.9%), 149 of 432 patients (34.5%), and 341 of 385 patients (88.6%) in the too early, timely, and too late groups, respectively (P < .001). Patients in the too early group underwent more parenchyma-sparing resections (too early group, 123 of 438 [28.1%]; timely group, 40 of 504 [7.9%]; too late group, 5 of 497 [1.0%]; P < .001), while morbidity (too early group, 112 of 438 [25.6%]; timely group, 117 of 504 [23.2%]; too late group, 158 of 497 [31.8%]; P = .002) and mortality (too early group, 4 patients [0.9%]; timely, 4 [0.8%]; too late, 13 [2.6%]; P = .03) were highest in the too late group. Of the 497 patients in the too late group, 124 (24.9%) had a previous history of watch-and-wait care. CONCLUSIONS AND RELEVANCE: Until the biology and progression patterns of IPMN are clarified and accurate guidelines established, a watch-and-wait policy should be applied with caution, especially in IPMN bearing a main-duct component. One-third of IPMNs reach the cancer stage before resection. At specialized referral centers, the risks of surgical morbidity and mortality are justifiable.
引用
- Tjaden C, Sandini M, Mihaljevic AL, et al. Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. JAMA Surg. 2021. PMID: 34009233. doi:10.1001/jamasurg.2021.0950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。